Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Multivitamins: Cancer among men - Nutraceuticals World

What are you searching for?

Sign in
Research

Multivitamins: Cancer among men

Author Image

By: Sean Moloughney

Editor, Nutraceuticals World

Nutraceutical: Multivitamins

Indication: Cancer among men

Source: JAMA 2012;308(18):1871-1880

Research: Multivitamin preparations are the most common dietary supplement, taken by at least one-third of all U.S. adults. This study aimed to determine if long-term multivitamin supplementation decreases the risk of total and site-specific cancer events among men. A large-scale, randomized, double-blind, placebo-controlled trial (Physicians’ Health Study II) of 14,641 male U.S. physicians initially aged 50 years or older (mean [SD] age, 64.3 [9.2] years), including 1,312 men with a history of cancer at randomization, enrolled in a common multivitamin study that began in 1997 with treatment and follow-up through June 1, 2011. Subjects received a daily multivitamin or placebo. Main outcome measures included total cancer (excluding non-melanoma skin cancer), with prostate, colorectal and other site-specific cancers among the secondary end points.

Results: During a median (interquartile range) follow-up of 11.2 (10.7-13.3) years, there were 2,669 men with confirmed cancer, including 1,373 cases of prostate cancer and 210 cases of colorectal cancer. Compared with placebo, men taking a daily multivitamin had a statistically significant reduction in the incidence of total cancer (multivitamin and placebo groups, 17.0 and 18.3 events, respectively, per 1,000 person-years; hazard ratio [HR], 0.92; 95% CI, 0.86-0.998; P = .04). According to results, there was no significant effect of a daily multivitamin on prostate cancer (multivitamin and placebo groups, 9.1 and 9.2 events, respectively, per 1,000 person-years; HR, 0.98; 95% CI, 0.88-1.09; P = .76), colorectal cancer (multivitamin and placebo groups, 1.2 and 1.4 events, respectively, per 1,000 person-years; HR, 0.89; 95% CI, 0.68-1.17; P = .39), or other site-specific cancers. There was no significant difference in the risk of cancer mortality (multivitamin and placebo groups, 4.9 and 5.6 events, respectively, per 1,000 person-years; HR, 0.88; 95% CI, 0.77-1.01; P = .07). Daily multivitamin use was associated with a reduction in total cancer among 1,312 men with a baseline history of cancer (HR, 0.73; 95% CI, 0.56-0.96; P = .02), but this did not differ significantly from that among 13,329 men initially without cancer (HR, 0.94; 95% CI, 0.87-1.02; P = .15; P for interaction = .07). Researchers concluded that in this large prevention trial of male physicians, daily multivitamin supplementation modestly but significantly reduced the risk of total cancer.

Add us as a preferred source on Google

Get the latest Nutraceuticals World news, insights and analysis in your Google Search and AI experiences.

Add Nutraceuticals World as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Nutraceuticals World Newsletters

Topics